Finance

Beta
Lists
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$57.33
+1.47%
(+0.83) 1D
$57.50
+0.30% (+0.17)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMRN...
Open
$56.83
High
$57.79
Low
$56.52
Mkt. cap
11.08B
Avg. vol.
2.35M
Volume
1.60M
P/E ratio
41.83
52-wk high
$66.28
52-wk low
$49.26
EPS
$1.37
Beta
0.25
Shares outstanding
193.28M
No. of employees
3K
Open
$56.83
High
$57.79
Low
$56.52
Mkt. cap
11.08B
Avg. vol.
2.35M
Volume
1.60M
P/E ratio
41.83
52-wk high
$66.28
52-wk low
$49.26
EPS
$1.37
Beta
0.25
Shares outstanding
193.28M
No. of employees
3K
News stories
From sources across the web
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com
Analyst Ratings
Based on 20 analysts giving stock ratings to BMRN in the past 3 months
Strong Buy
Buy
15
Hold
5
Sell
0
12 month forecast
Based on 20 Wall Street analysts offering 12 month price targets for BMRN in the last 3 months.
Highest
Current $57.33
$120.00 (+109.31%)
Average
$87.00 (+51.75%)
Lowest
$50.00 (-12.79%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
$50.00
-12.8%
06/22/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$86.00
+50%
06/03/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$80.00
+39.5%
05/29/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$68.00
+18.6%
05/24/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$111.00
+93.6%
05/22/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
05/22/2026
Akash Tewari
Jefferies
Buy
Maintained
$104.00
+81.4%
05/21/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$120.00
+109.3%
05/21/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$82.00
+43%
05/21/2026
Yun Zhong
Wedbush
Buy
Reiterated
$94.00
+64%
05/21/2026
Phil Nadeau
TD Cowen
Buy
Maintained
$120.00
+109.3%
05/21/2026
Eric Joseph
Citi
Buy
Maintained
$80.00
+39.5%
05/20/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$80.00
+39.5%
05/20/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$75.00
+30.8%
05/21/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$80.00
+39.5%
05/19/2026
Eliana Merle
Barclays
Buy
Reiterated
$105.00
+83.2%
05/21/2026
Unknown Analyst
Citi
Buy
Initiated
-
-
05/19/2026
Joseph Schwartz
Leerink Partners
Hold
Reiterated
$62.00
+8.1%
05/18/2026
Salveen Richter
Goldman Sachs
Hold
Initiated
$69.00
+20.4%
05/11/2026
Luca Issi
RBC Capital
Hold
Maintained
$66.00
+15.1%
05/04/2026
William Pickering
Bernstein
Buy
Reiterated
$82.00
+43%
05/05/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$119.00
+107.6%
05/06/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/03/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$85.00
+48.3%
03/02/2026
Sami Corwin
William Blair
Hold
Maintained
-
-
02/24/2026
Last report
May 4, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.76 / $0.91
-16.86%miss
Revenue / Est. (USD)
766.21M / 751.68M
+1.93%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
825.41M
776.13M
874.56M
766.21M
Cost of goods sold
311.40M
549.56M
348.91M
373.80M
Cost of revenue
311.40M
549.56M
348.91M
373.80M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
232.28M
268.42M
324.16M
249.98M
Operating expense
237.12M
273.26M
329.01M
254.46M
Total operating expenses
548.52M
822.82M
677.92M
628.26M
Operating income
276.89M
-46.69M
196.64M
137.95M
Other non operating income
4.83M
5.09M
1.02M
3.96M
EBT including unusual items
297.87M
-26.32M
-27.15M
141.20M
EBT excluding unusual items
297.87M
-26.32M
214.10M
149.52M
Income tax expense
57.34M
4.42M
19.42M
35.68M
Effective tax rate
19.25%
-16.79%
-71.52%
25.27%
Other operating expenses
-
-
-
-
Net income
240.53M
-30.74M
-46.57M
105.53M
Net profit margin
29.14%
-3.96%
-5.33%
13.77%
Earnings per share
1.44
0.12
0.46
0.76
Interest and investment income
18.83M
17.85M
19.21M
22.56M
Interest expense
-2.68M
-2.58M
-2.78M
-14.96M
Net interest expenses
16.15M
15.28M
16.43M
7.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
295.45M
-28.20M
209.68M
154.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer